Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
Long Term Effects of Eltrombopag Treatment Versus Placebo for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia (EQoL-MDS): Interim Results of a Single-Blind, Randomised, Controlled, Phase II Superiority Trial
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes – Clinical Studies: Poster II Hematology Disease Topics &...
Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes—Clinical Studies: Poster I Hematology Disease Topics & Pathways: Diseases,...
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase Ib Results
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 637. Myelodysplastic Syndromes – Clinical Studies: Combination Therapies Hematology...
Myelodysplastický syndrom – co přinesl ASH® 2019
11 septembra, 2020 7:51 pmNa prvém místě jmenuji dvě velmi důležité práce týkající se přesnější stratifikace nemocných a stanovení prognózy. U myelodysplastického syndromu (MDS) nalezneme minimálně jednu...
A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children
11 septembra, 2020 7:51 pmProgram Oral and Poster Abstracts Session 311. Disorders of Platelet Number or Function: Poster II Hematology Disease Topics...
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 311. Disorders of Platelet Number or Function: Advances in ITP...
Phase II Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 311. Disorders of Platelet Number or Function: Advances in ITP...
Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Type: Oral Session: 311. Disorders of Platelet Number or Function: Clinical Insights into...
Imunitní trombocytopenie – zajímavosti z ASH®
11 septembra, 2020 7:51 pmV rámci každoročního kongresu Americké hematologické společnosti, který se konal ve dnech 7.–10. prosince 2019 v Orlandu na Floridě (Spojené státy americké) bylo prezentováno...
The Impact of Treatment Recommendation By Leukemia Artificial Intelligence Program (LEAP) on Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
11 septembra, 2020 7:51 pmProgram: Oral and Poster Abstracts Session: 632. Chronic Myeloid Leukemia: Therapy: Poster I Hematology Disease Topics & Pathways:...